Final answer:
Initiating a patient on a proton pump inhibitor (PPI) therapy can increase the risk of developing C. difficile infections and other infections. Patients should be aware of these potential risks and report any symptoms of infection to their healthcare provider.
Step-by-step explanation:
One potential risk of initiating a patient on a proton pump inhibitor (PPI) therapy that should be reviewed with the patient is an increased risk of developing C. difficile infections. The use of PPIs can disrupt the normal balance of bacteria in the gut, which can promote the growth of C. difficile bacteria and lead to infection.
Additionally, PPIs can also increase the risk of other infections, such as respiratory tract infections and urinary tract infections. This is because PPIs reduce the production of stomach acid, which can weaken the body's natural defense against pathogens.
It is important for the patient to be aware of these potential risks and to report any symptoms of infection to their healthcare provider.